Crystallization

Crystallization stands as the ultimate step in drug substance manufacturing, preceding isolation and drying. Its significance lies in the multifaceted advantages it provides, making it indispensable for chemists and process engineers in the biotech and pharmaceutical industries. 

However, crystallization is often complex and requires careful optimization, as each active ingredient or intermediate demands its own specific conditions to achieve the best results. This complexity has made crystallization a rich area for research and innovation. In response, APC has emerged from the University College Dublin labs of Professor Brian Glennon, a leading expert in the field.  Over the last decade the company has grown to be a powerhouse innovator and thought leader in crystallization, employing over 300 people with an unrivalled depth and breadth of experience in solving the most challenging crystallization problems including:

Nucleation Control

The control of particle size distribution (PSD) is of primary importance in pharmaceutical crystallization. Downstream processes like filtration or drying are significantly influenced by the properties of the PSD. Variability in the final PSD is mainly attributed to uncertainties in nucleation rates. Therefore, achieving the desired PSD necessitates a precise control of nucleation events.

In many cases, adopting Continuous Processing for Crystallization can be an effective strategy for ensuring consistent nucleation control, leading to more predictable and reproducible particle size distributions.

Heterogeneous Mechanisms

Nucleation predominantly occurs via heterogeneous mechanisms, where the nucleus forms on a surface or interface rather than in bulk solution. In large-scale industrial processes, heterogeneous nucleation can be undesirable due to vessel fouling and lower product yield. However, nucleants are often strategically added to induce nucleation and produce a particular polymorph via heterogeneous nucleation.

Particle Size Distribution

The distribution of particle sizes within a batch significantly impacts downstream processes. This metric refers to the range of particle sizes within a crystalline batch, and its meticulous control is imperative for downstream processes. The significance of particle size distribution lies in its impact on essential factors such as drug bioavailability, dissolution rates, and formulation characteristics. Achieving a uniform and targeted particle size distribution demands careful consideration during the crystallization process. Factors influencing particle size distribution include nucleation and growth kinetics, solvent selection, and process parameters. Robust analytical techniques, including laser diffraction and microscopy, play a pivotal role in assessing and controlling particle size distribution. A nuanced understanding and effective management of particle size distribution contribute not only to the optimization of manufacturing processes but also to meeting regulatory standards and ensuring the consistent quality of pharmaceutical products.

Solubility and Supersaturation

Maintaining the right balance between solubility and supersaturation is critical for successful crystallization. This section will discuss approaches for controlling supersaturation levels through careful selection of solvents and temperature control.

Developing an efficient crystallization process starts with choosing the right solvent and designing your crystallization faster. Optimizing solvent selection and achieving a rapid process design can accelerate overall project timelines while maintaining the required product quality.

Harnessing the most appropriate analytical tools to understand and address crystallization challenges

1. In-Situ Monitoring: Within the analytical considerations of crystallization process development, in-situ monitoring assumes a paramount role, leveraging specific instrumentation for real-time data acquisition and adaptive control. This method transcends traditional off-line approaches, employing advanced techniques like in-situ spectroscopy, microscopy, and particle size analyzers. Spectroscopic methods, such as near-infrared (NIR), Fourier-transform infrared spectroscopy (FTIR), and Raman spectroscopy, enable continuous monitoring of chemical composition during crystallization. Microscopy, with tools like in-situ imaging, provides detailed insights into particle morphology and growth. Concurrently, particle size analyzers, particularly laser diffraction and FBRM instruments, offer continuous measurement of crystal dimensions. This suite of equipment, available at APC along with the team with experience of using these tools on a daily basis, facilitates a granular understanding of nucleation, crystal growth kinetics, and other dynamic events. In-situ monitoring, executed through these sophisticated instruments, not only sharpens process control but also elevates the overall precision and reproducibility of crystallization processes of our client’s medicines.

   For difficult-to-control processes, strategies such as Thermal Cycling for Crystallization Control can be employed to manage crystal growth and ensure a uniform PSD while mitigating unwanted transformations in crystal form.

2. Characterization of Crystal Properties: Within the modeling considerations of crystallization process development, population balance models (PBMs) represent a sophisticated and indispensable tool for gaining comprehensive insights into crystal size distribution evolution. PBMs delve into the intricate dynamics of crystal growth and nucleation, offering a mathematical framework to predict the evolution of particle sizes over time. Typically applied in tandem with computational methods, PBMs aid in optimizing crystallization processes by accounting for diverse mechanisms influencing particle size distribution. By employing PBMs, researchers can integrate complex parameters such as breakage, aggregation, and growth kinetics into a unified model, providing a nuanced understanding of the crystallization journey. The utilization of PBMs enhances the precision of process control, facilitating the design of crystallization processes with targeted and reproducible particle size distributions—a critical aspect in ensuring the quality and consistency of pharmaceutical products.

   Additionally, an effective crystallization strategy must consider the downstream effects of drying, especially how to control crystal form transformation during drying to ensure the desired polymorphic form is retained.

Leveraging in silico modelling to enhance and accelerate development of crystallization processes

1. Kinetics and Thermodynamics: Understanding the kinetics and thermodynamics of crystallization is fundamental for process optimization. This section will explore mathematical modeling approaches to predict crystal growth, nucleation rates, and thermodynamic equilibrium. Within the analytical considerations of crystallization process development, in-situ monitoring assumes a paramount role, leveraging specific instrumentation for real-time data acquisition and adaptive control. This method transcends traditional off-line approaches, employing advanced techniques like in-situ spectroscopy, microscopy, and particle size analyzers. Spectroscopic methods, such as near-infrared (NIR), Fourier-transform infrared spectroscopy (FTIR), and Raman spectroscopy, enable continuous monitoring of chemical composition during crystallization. Microscopy, with tools like in-situ imaging, provides detailed insights into particle morphology and growth. Concurrently, particle size analyzers, particularly laser diffraction instruments, offer continuous measurement of crystal dimensions. This suite of equipment facilitates a granular understanding of nucleation, crystal growth kinetics, and other dynamic events. In-situ monitoring, executed through these sophisticated instruments, not only sharpens process control but also elevates the overall precision and reproducibility of crystallization processes in pharmaceutical development.

2. Population Balance Models: Population balance models (PBMs) represent a sophisticated and indispensable tool for gaining comprehensive insights into crystal size distribution evolution. PBMs delve into the intricate dynamics of crystal growth and nucleation, offering a mathematical framework to predict the evolution of particle sizes over time. Typically applied in tandem with computational methods, PBMs aid in optimizing crystallization processes by accounting for diverse mechanisms influencing particle size distribution. By employing PBMs, researchers can integrate complex parameters such as breakage, aggregation, and growth kinetics into a unified model, providing a nuanced understanding of the crystallization journey. The utilization of PBMs enhances the precision of process control, facilitating the design of crystallization processes with targeted and reproducible particle size distributions—a critical aspect in ensuring the quality and consistency of pharmaceutical products.

   For more challenging crystallization cases, APC’s expertise in developing scale-up strategies for challenging crystallization processes ensures that lab-scale success is translated effectively into commercial-scale production without loss of yield or purity.

Outsourcing Considerations for Crystallization Process Development

Outsourcing crystallization process development necessitates a comprehensive assessment across multifaceted dimensions to ensure an optimal partnership.

1. Expertise & Experience: The linchpin of outsourcing considerations resides in the expertise and experience of potential partners in crystallization techniques. A partner boasting a rich tapestry of accomplishments, underscored by a proven track record and diversified experience in managing a spectrum of projects, becomes an invaluable asset. This wealth of knowledge and seasoned proficiency not only instills confidence but also equips the partner with unparalleled problem-solving capabilities. This depth of expertise becomes a cornerstone for successful crystallization process development, offering a nuanced and well-informed approach tailored precisely to the unique intricacies of the pharmaceutical industry.

2. Equipment Capabilities: A critical facet in the selection process involves a meticulous examination of the outsourcing partner's equipment capabilities. The adage "the right tools for the right job" holds particularly true in the realm of crystallization. A partner armed with a state-of-the-art arsenal, encompassing advanced crystallization reactors and cutting-edge analytical instruments, signals a commitment to precision and efficiency. This comprehensive suite of tools not only assures compatibility with current project requirements but also reflects an anticipation of future technological advancements. The integration of such advanced methodologies ensures optimal crystallization outcomes, aligning the outsourcing partner with the dynamic technological landscape.

3. Flexibility & Scalability: The considerations extend to the inherent attributes of flexibility and scalability within an outsourcing partner's framework. Flexibility stands as the cornerstone of adaptability, ensuring the partner can tailor approaches to the unique demands of each project. This flexibility, intertwined with a commitment to staying agile, positions the partner to effectively respond to unforeseen challenges and evolving project dynamics. Simultaneously, scalability emerges as a pivotal factor, demonstrating the partner's ability to accommodate shifts in project scope or scale. An outsourcing partner showcasing these attributes is not merely a service provider but a strategic collaborator, adept at navigating the diverse terrains of crystallization across varying scales and complexities.

4. Phase Appropriateness: The journey of a pharmaceutical product through its developmental stages necessitates a nuanced and adaptable approach to crystallization processes. Embracing a phase-appropriate strategy becomes paramount, acknowledging the distinct needs and objectives at each developmental stage. In the early stages, emphasis lies on rapid exploration and identification of crystallization routes, seeking to understand the fundamental properties of the compound. As the product progresses through preclinical and clinical phases, the focus shifts towards refining and optimizing the crystallization process for scalability and reproducibility. At the commercialization stage, robustness and efficiency become pivotal. This phase-appropriate mindset ensures that the crystallization process evolves in tandem with the evolving requirements, striking a delicate balance between exploration, optimization, and robust commercial production. The ability to seamlessly transition through these phases underscores the adaptability and strategic foresight required in crystallization process development within the pharmaceutical industry.

Conclusion

The challenges encountered in crystallization process development, such as nucleation control and crystal size distribution, underscore the complexity of achieving consistent and reproducible outcomes. Innovative approaches in process design, analytical considerations, and modeling play pivotal roles in overcoming these challenges, ensuring the efficiency and reliability of the crystallization process.

As the pharmaceutical landscape evolves, outsourcing crystallization process development emerges as a strategic option. Considerations such as expertise, equipment capabilities, phase-appropriateness of the proposed development and scalability of the processes developed are vital in determining the suitability of outsourcing partners.

Ultimately, whether pursued in-house or outsourced, a well-developed crystallization process is fundamental for meeting stringent quality standards. By understanding and navigating the challenges, industry professionals can not only enhance the efficiency of downstream processes but also contribute to the overall success of drug development and manufacturing.

Frequently Asked Questions

Schedule a one-on-one meeting to dive deeper into our solutions.